🟢 Clearpoint Neuro is trading 5.83% up in pre-market with no fresh company-specific announcement identified

Clearpoint Neuro is trading at $14.27, up +5.83% before September 11, 2026, with no fresh company-specific announcement identified.

• S&P 500 futures are up 0.53%, while Nasdaq futures gain 0.61%, reflecting a firmer broader pre-market tone.
• Partner Aspen Neuroscience’s FDA RMAT designation was announced July 31, 2026, making it unlikely to explain this overnight move.
• The move may reflect broader risk sentiment or trading activity rather than a confirmed ClearPoint catalyst.